Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN)

Q: What does CUSIP 29337E102 represent in this 13F holders report?

CUSIP 29337E102 is the security identifier for ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q2 2023?

61 institutional investors reported ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q2 2023. Use the holders table for investor-level position and value details.

CUSIP: 29337E102

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 58,923,077
Total 13F shares: 39,092,843
Share change: +5,535,094
Total reported value: $797,915,923
Put/Call ratio: 0%
Price per share: $20.41
Number of holders: 61
Value change: +$112,876,379
Number of buys: 43
Number of sells: 16

Quarterly Holders Quick Answers

What is CUSIP 29337E102?
CUSIP 29337E102 identifies ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2023
Previous quarter: Q1 2023

Recent filing periods for CUSIP 29337E102:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ORBIMED ADVISORS LLC	13F	Company	15%	8,996,213	$197,017,065	—	31 Mar 2023	13F
5AM Venture Management, LLC	13F	Company	9.8%	5,798,475	$126,986,603	—	31 Mar 2023	13F
FMR LLC	13F	Company	5.4%	3,163,482	$69,280,255	—	31 Mar 2023	13F
David P. Bonita	3/4/5	Director, 10%+ Owner	— mixed-class rows	4,207,568 mixed-class rows	$63,552,894	—	02 Jun 2022	3/4/5
CITADEL ADVISORS LLC	13F	Company	3.9%	2,296,210	$50,286,999	—	31 Mar 2023	13F
VR Adviser, LLC	13F	Company	3.8%	2,214,142	$48,489,710	—	31 Mar 2023	13F
RA CAPITAL MANAGEMENT, L.P.	13F 3/4/5	Company · Former 10% owner	3.6%	2,122,465	$46,481,984	—	31 Mar 2023	13F 3/4/5
Cormorant Asset Management, LP	13F	Company	3.3%	1,936,133	$42,401,000	—	31 Mar 2023	13F
Fairmount Funds Management LLC	13F	Company	3.3%	1,924,938	$42,156,142	—	31 Mar 2023	13F
New Enterprise Associates 14, L.P.	3/4/5	10%+ Owner	— class O/S missing	2,611,050	$39,518,242	—	05 Apr 2022	3/4/5
Commodore Capital LP	13F 3/4/5	Company · 10%+ Owner	2.9%	1,731,365	$37,916,894	—	31 Mar 2023	13F 3/4/5
Mark Chin	3/4/5	Director	— mixed-class rows	2,352,572 mixed-class rows	$35,477,530	—	02 Jun 2022	3/4/5
Braden M. Leonard	3/4/5	10%+ Owner	— class O/S missing	1,997,774	$30,236,309	—	03 Jan 2023	3/4/5
Barbara Dalton	3/4/5	Director	— mixed-class rows	1,566,222 mixed-class rows	$23,576,122	—	02 Jun 2022	3/4/5
Frazier Life Sciences Management, L.P.	13F	Company	1.4%	830,983	$18,198,528	—	31 Mar 2023	13F
Boxer Capital, LLC	13F	Company	1.2%	710,644	$15,563,000	—	31 Mar 2023	13F
JANUS HENDERSON GROUP PLC	13F	Company	1%	602,154	$13,183,336	—	31 Mar 2023	13F
Carl Goldfischer	3/4/5	Director	— mixed-class rows	711,880 mixed-class rows	$10,645,656	—	02 Jun 2022	3/4/5
Logos Global Management LP	13F	Company	0.68%	401,229	$8,786,915	—	31 Mar 2023	13F
BML Capital Management, LLC	13F	Company	0.36%	212,179	$4,646,720	—	31 Mar 2023	13F
David M. Mott	3/4/5	Director	— mixed-class rows	237,724 mixed-class rows	$3,469,305	—	02 Jun 2022	3/4/5
VANGUARD GROUP INC	13F	Company	0.26%	151,914	$3,326,917	—	31 Mar 2023	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.12%	70,258	$1,539,000	—	31 Mar 2023	13F
JBF Capital, Inc.	13F	Company	0.08%	50,050	$1,096,095	—	31 Mar 2023	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.08%	46,874	$1,027,000	—	31 Mar 2023	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.07%	41,411	$906,901	—	31 Mar 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.06%	35,388	$774,997	—	31 Mar 2023	13F
BlackRock Finance, Inc.	13F	Company	0.06%	33,795	$740,110	—	31 Mar 2023	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.05%	30,979	$678,440	—	31 Mar 2023	13F
Kenneth Attie	3/4/5	SVP, CMO	— mixed-class rows	68,200 mixed-class rows	$516,104	—	28 Jan 2022	3/4/5
Michael Gray	3/4/5	CFO & COO	— class O/S missing	27,610	$417,877	—	22 Feb 2023	3/4/5
JANE STREET GROUP, LLC	13F	Company	0.03%	18,444	$403,924	—	31 Mar 2023	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.03%	17,950	$393,105	—	31 Mar 2023	13F
MORGAN STANLEY	13F	Company	0.03%	17,418	$381,454	—	31 Mar 2023	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.03%	17,167	$375,957	—	31 Mar 2023	13F
Bank of New York Mellon Corp	13F	Company	0.03%	15,295	$334,961	—	31 Mar 2023	13F
MIRABELLA FINANCIAL SERVICES LLP	13F	Company	0.02%	11,670	$255,573	—	31 Mar 2023	13F
CITIGROUP INC	13F	Company	0.02%	11,263	$246,660	—	31 Mar 2023	13F
DIMENSIONAL FUND ADVISORS LP	13F	Company	0.02%	9,915	$217,138	—	31 Mar 2023	13F
STATE STREET CORP	13F	Company	0.02%	9,424	$206,386	—	31 Mar 2023	13F
Cubist Systematic Strategies, LLC	13F	Company	0.02%	8,986	$196,793	—	31 Mar 2023	13F
BARCLAYS PLC	13F	Company	0.01%	7,227	$158,271	—	31 Mar 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.01%	6,545	$143,335	—	31 Mar 2023	13F
PRELUDE CAPITAL MANAGEMENT, LLC	13F	Company	0.06%	34,062	$39,989	—	31 Mar 2023	13F
Tower Research Capital LLC (TRC)	13F	Company	0%	1,657	$36,000	—	31 Mar 2023	13F
Dorsey Wright & Associates	13F	Company	0%	1,237	$27,090	—	31 Mar 2023	13F
Point72 Asset Management, L.P.	13F	Company	0%	746	$16,337	—	31 Mar 2023	13F
ROYAL BANK OF CANADA	13F	Company	0%	486	$11,000	—	31 Mar 2023	13F
UBS Group AG	13F	Company	0%	334	$7,315	—	31 Mar 2023	13F
Middle East Fze Point72	13F	Individual	0%	293	$6,417	—	31 Mar 2023	13F

Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) as of Q2 2023

As of 30 Jun 2023, Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) was held by 61 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 39,092,843 shares. The largest 10 holders included ORBIMED ADVISORS LLC, 5AM Venture Management, LLC, FMR LLC, COMMODORE CAPITAL LP, CITADEL ADVISORS LLC, VR Adviser, LLC, Fairmount Funds Management LLC, RA CAPITAL MANAGEMENT, L.P., Cormorant Asset Management, LP, and BlackRock Inc.. This page lists 61 institutional shareholders reporting positions in this security for the Q2 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 holders

Q2 2023 holders

Holder diff

Investor	Q1 2023 Shares	Q2 2023 Shares	Share Diff	Share Chg %	Q1 2023 Value $	Q2 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.